Generex Biotechnology Corporation(OTCMKTS:GNBT) Holds Out On Promise


Dallas, Texas 03/10/2014 (FINANCIALSTRENDS) – Generex Biotechnology Corporation(OTCMKTS:GNBT)  is one of the leading drug delivery pharmaceutical , bio-technology majors where the innovative solution has helped define relief and better therapy solutions for those suffering from chronic health conditions. In the case of Generex, its prime property is the diabetes delivery solutions.

Generex Biotechnology Corporation(OTCMKTS:GNBT) achieved this solution, following an extended phase of trial, research and development. The core medical principleis the higher rate of absorption of drugs by the inner lining of the mouth, over an injection. It has been found that when the drug is placed along the buccal tissues, the rate of delivery of the drug is very easy. Additionally, many companies such as Eli Lilly, which was interested in this line of technology for delivery of drugs invested over $1 million in developing it. However, for the company other products drew attention and soon it withdrew itself from the same. Others who did venture into alternative drug delivery technology development included- Pfizer, which even bought out $2.8 billion in acquiring Nektar Therapeutics, a company which developed the aerosol-based technology for absorption of the drug for treatment of diabetes. Pfizer debuted this as Exubera, but soon lost interest, as both patients and doctors themselves did not recommend lung-absorption based drug delivery system.

Generex Biotechnology Corporation(OTCMKTS:GNBT)has however great scope for the development of diabetes alternative drug delivery system, as it has now licensed the research cycles to an India-based firm – Shrey Life Sciences Pvt. Ltd. The company will now complete the Phase III trial of Oral-lyn, which is designed to be delivered as an injection. The eventual stage of evolution for this drug could be an aerosol-based form factor.  Considering India is one of the leading diabetes positive populations, innovation with respect to drug delivery for diabetes is likely to develop from research organizations, based out of Asia.